A 7-yr-old girl presented with isosexual precocious puberty secondary to a feminizing adrenal adenoma. The adrenal tumor was found to express aromatase messenger ribonucleic acid. Enzyme kinetic studies revealed a high level of aromatase activity in the adrenal tumor, with a K m of 45 nmol/L and a maximum velocity of 25.6 pmol/mg⅐h. Aromatase activity was approximately 500-fold higher in the tumor than in adjacent normal adrenal tissue. Although histopathological examination of the tumor was most consistent with a benign adenoma, the aromatase transcripts present in the tumor corresponded to those previously associated with malignant as well as benign tumors. We consider the pattern of aromatase expression sufficient to warrant continued follow-up for tumor recurrence. Our case demonstrates that isosexual precocious puberty secondary to a feminizing adrenal tumor can be due to estrogen synthesis from the tumor itself rather than peripheral aromatization as had been previously theorized. (J Clin Endocrinol Metab 86: 649 -652, 2001) F EMINIZING ADRENAL tumors are a rare cause of isosexual precocious puberty in females (1). The mechanism of estrogen production in feminizing adrenal tumors has been proposed to be due to either peripheral aromatization of androgens (2) or estrogen production from the tumor itself (3). Increased aromatase messenger ribonucleic acid (mRNA) expression and activity have been demonstrated in a feminizing adrenocortical carcinoma from an adult male presenting with gynecomastia (4), presumably accounting for estrogen production by the tumor. We encountered a 7-yr-old female who presented with isosexual precocious puberty and adrenal adenoma. The adenoma was shown to possess high aromatase P450 activity and to express exon PII-and I.3-containing aromatase mRNA transcripts. To our knowledge, this is the first report of increased aromatase (CYP19) gene expression in an adrenal adenoma resulting in isosexual precocious puberty in a child.
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Case Report
A 7 9/12-yr-old Caucasian female presented with a 1-yr history of pubic hair development and a 1-month history of breast development. Physical examination revealed Tanner II pubic hair and Tanner II breasts. There was no virilization. Her bone age was advanced at 10 yr. Initial hormonal studies were notable for serum estradiol of 21 pg/mL (77 pmol/L), LH below 0.1 IU/L, and FSH below 0.3 IU/L. Six months later, her breast development had progressed to Tanner III. Her interval growth velocity was in the pubertal range at 13.6 cm/yr. Her predicted final adult height was 155 cm, based on Bayley and Pinneau height prediction tables (5), whereas her calculated midparental height was 158 cm.
Menarche occurred at 8 9/12 yr, and by 9 yr of age the patient had developed dysfunctional uterine bleeding. She was treated with high dose ethinyl estradiol/norgestril, which resulted in cessation of menses. Menorrhagia and menstrual cramping occurred when treatment was discontinued, prompting a pelvic ultrasound. The ultrasound revealed a 6-cm, well circumscribed right adrenal mass. Laboratory studies at this time (Table 1) showed elevations of serum estrone and dehydroepiandrosterone sulfate. Twentyfour-hour urine studies (Table 2) showed increased 17-ketosteroids, estrone, estradiol, and estriol relative to adult female normal values. Urinary 17-hydroxycorticosteroid and free cortisol levelswere normal. However, overnight low dose (1 mg) and high dose (2 mg, three times daily, for 3 days) dexamethasone did not suppress her serum cortisol [morning serum cortisol concentrations after low and high dose dexamethasone treatments were 7.4 g/dL (204.2 nmol/L) and 7.4 g/dL (204.2 nmol/L), respectively]. Chest, abdominal, and pelvic computed tomography scans did not show any evidence of tumor metastasis.
The patient underwent a complete right adrenalectomy without complications. The weight of the well encapsulated adrenal mass was 66 g. Pathological examination was consistent with adrenal adenoma. There were few mitotic cells, no atypical mitotic figures, and no evidence of vascular invasion. Tumor tissue and adjacent normal adrenal tissue were frozen in liquid nitrogen and stored at Ϫ70 C.
One month after surgery, the patient's serum dehydro-epiandrosterone sulfate and estrone levels were normal, as was urinary 17-ketosteroid excretion. An overnight low dose dexamethasone suppression test showed normal suppression (morning cortisol, Ͻ0.2 g/dL; Ͻ5.5 nmol/L). Follow-up adrenal computed tomography scans at 7 months and 1 yr after surgery revealed no residual or recurrent tumor. The patient resumed menses at the age of 10 8/12 yr. Her final height is 150.9 cm.
Materials and Methods

Aromatase activity assay
Aromatase activity was determined by [ 3 H]H 2 O release assay using homogenates prepared as described by Kadohoma et al. (6) . [1␤-N-3 H]Androst-4-ene-3,17-dione was used as substrate. Enzyme kinetic analyses were performed at six different substrate concentrations
Analysis at 100 nmol/L substrate was performed using NCI-H295 cell extract to validate our assay results.
RT-PCR Southern blot analysis
Exon I primer-specific RT-PCR has been shown to be a useful tool for examining the alternative use of aromatase gene exon I promoters in aromatase-expressing tissues (7, 8) . We synthesized seven oligonucleotides (7, 8) , including the 1a, 1b, 1c, 15, N69, 1d, and 2a sequences described by Harada (7), Toda et al. (9) , and Shozu et al. (10) . These primers have sequences derived from exons I.1, I.3, I.4, I.5, I.6, pII, and II, respectively. A reverse primer (2d) with a sequence derived from exon II and situated downstream from 2a was also used. The membranes were hybridized with an exon II-specific oligonucleotide probe that corresponds to the middle of exon II (5Ј-ATGGTTTTGGAAATGCTGAA-3Ј). A schematic representation of the relative locations of five exons I in the human aromatase gene and the positions of the primers used in our primer-specific RT-PCR analysis are shown in Fig. 1 .
Total RNA was isolated from the tumor and normal adrenal tissue as described by Chomczynski (11) . RT-PCR was performed at nonsaturating conditions using the Titan One Tube RT-PCR System (Roche, Indianapolis, IN) (8) .
Results
In vitro aromatase activity in the tumor tissue was substrate concentration-dependent. The K m and maximum velocity (V max ) values derived from a double reciprocal plot (Fig. 2) were 45 nmol/L and 25.6 pmol/mg⅐h, respectively. The K m value was comparable to that determined for human placenta aromatase expressed in CHO cells (31 nmol/L) (6). The V max value for aromatase in our adrenal tumor homogenate was only one fourth of that measured in a microsomal preparation from a feminizing adrenocortical tumor in a 29-yr-old man (4). However, because the amount of tumor tissue and normal adrenal tissue was limited, we performed the enzyme assay using an unfractionated tissue homogenate rather than a microsomal preparation. The specific activity would presumably be significantly higher if the assay were performed using a microsomal preparation. Of note, activity in normal adrenal tissue adjacent to the tumor was very low, approximately 0.2% of that seen with the tumor tissue. The low activity in normal adrenal tissue prevented an accurate determination of kinetic parameters. We also performed a comparative study using the NCI-H295 human adrenocortical carcinoma cell line, which is known to express aromatase (12, 13) . Aromatase activity in the NCI-H295 cell lysates, measured at a 100 nmol/L substrate concentration, was determined to be 0.28 pmol/mg⅐h. After incubating the cells with 8-bromo-cAMP for 24 h, aromatase activity increased to 0.52 pmol/mg⅐h. These results were similar to those obtained by Sanderson et al. (14) , supporting the validity of our assay conditions. Of note, the aromatase specific activity in the NCI-H295 cells was much lower than that in homogenates of our patient's adrenal tumor measured at the same 100 nmol/L substrate concentration (ϳ20 pmol/mg⅐h).
Human aromatase gene exon I-specific primer RT-PCR analysis revealed that the aromatase P450 mRNA species in the adrenal tumor were mainly exon PII derived, suggesting that aromatase expression in this tumor was primarily driven by promoter II. Unspliced promoter I.3-driven transcripts (I.3 A) were also detected in the adrenal tumor (Fig. 3) . The level of aromatase mRNA in normal adrenal tissue was undetectable by RT-PCR.
Discussion
Although feminization secondary to an adrenal tumor has previously been attributed to peripheral conversion of adrenal androgen (2), our case confirms that an adrenal adenoma can possess the molecular pathways necessary for estrogen biosynthesis and that it can cause isosexual precocious puberty in a female. This conclusion is based on direct determination of aromatase activity in our patient's tumor, which was approximately 500 times higher than that in the adjacent, normal adrenal tissue.
In humans, estrogen is derived from the conversion of androstenedione, testosterone, and 16␣-hydroxyandrostenedione to estrone, estradiol, and estriol, respectively. Most of this conversion takes place in ovaries and adipose tissue, where it is catalyzed by aromatase P450. Normal adrenal tissue expresses very low level of aromatase P450. In our patient, the major circulating estrogen was estrone. The serum estrone presumably came from the aromatization of androstenedione by the adrenal adenoma. We speculate that estradiol was probably synthesized by conversion of estrone via peripheral 17␤-hydroxysteroid dehydrogenase type I (15), rather than intraadrenal aromatization of testosterone, as the peripheral testosterone level was unmeasurable. This interpretation is consistent with findings described by Young et al. (4) , who demonstrated tumor estrone (but not estradiol) production by direct catheterization of adrenal veins.
Analysis for aromatase mRNA expression in the tumor showed that Exon PII-containing mRNA was the major form detected, although unspliced promoter I.3 driven transcript (I.3 A) was also detected in the adrenal tumor. To our knowledge, this is the first report of exon I.3 mRNA expression in an adrenal adenoma. Exon PII-containing mRNA is normally expressed in gonadal tissue (16) and exon I.3-containing mRNA is normally expressed in adipose tissue (17) . Normal adult liver, endometrium, myometrium and adrenal tissues do not express exon PII or I.3-containing mRNA (16) . However, excessive expression of exon pII and I.3-containing mRNAs has been detected in various malignant and nonmalignant conditions, including endometriosis, leiomyoma, hepatocellular carcinoma, endometrial cancer, breast cancer, and adrenocortical cancer (16) . Promoters I.3 and II are both inducible by cAMP (17) . Thus, cAMP-dependent signaling is a potential mechanism for abnormal CYP-19 gene expression in our patient's adrenal tumor.
Several guidelines have been used to differentiate between adrenal carcinoma and adrenal adenoma on clinical grounds. These include weight, size of the tumor, and evidence of metastasis (18, 19) . Tumors weighing more than 500 g or having diameter greater than 6 cm are more likely to be carcinomas. Tissue histology is, of course, more definitive. Findings in carcinomas included abnormal mitoses, necrosis, vascular and capsular invasion, broad fibrous bands, and cellular pleomorphism. All of these features were absent in our patient. Therefore, we originally concluded that our patient's diagnosis was most consistent with an adenoma.
The urinary estrogen concentration in feminizing adrenal tumors has been reported to be a useful tool for following these patients. Very high concentrations indicate that the tumor is more likely to be a carcinoma (20) . Our patient's urinary estrogen was elevated in the range of some of the patients with adrenal carcinoma reported by Wotiz et al. (20) . Given the increased expression of exon I.3 and II mRNA, both of which are associated with multiple carcinomas (17) , and the extremely elevated urinary estrogen concentration, we have concluded that ongoing surveillance for recurrence of our patient's tumor is indicated.
This case illustrates the importance of ongoing monitoring and follow-up of patients with what appears to be simple or benign early puberty. Based on the large cross-sectional study of 17,000 girls by Herman-Giddens et al. (21) , precocious puberty has been defined as the onset of breast development before the age of 7 yr in white females (22) . When considering that our patient was 7 9/12 yr at presentation, and her predicted final adult height fell within her genetic potential, a thorough evaluation for pathological causes of precocious puberty was not undertaken. Her clinical course, however, became more concerning when she developed unremitting dysfunctional uterine bleeding associated with abdominal cramping. This prompted further investigation.
In summary, the present case is the first demonstration of increased aromatase P450 activity in a feminizing adrenal adenoma leading to isosexual precocious puberty. The aromatase activity was probably due to abnormal enhancement of the transcriptional activity of the promoter I.3 and II aromatase gene, a finding previously associated with malignancy. This association warrants careful longitudinal surveillance despite an otherwise good prognosis based on clinical pathological features most consistent with a benign adrenal adenoma.
